Share this article
Share this article
DES MOINES, Iowa, May 4, 2021 /PRNewswire/ Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, has been granted a United States patent (US 10,912,794) on the use of beta 1,3 glucan for modulating human immune function and treating intestinal inflammation. This new patent joins a previously issued patent (US 9,574,217) on the production of beta-glucan for immune modulation using algae from a proprietary strain of
Euglena gracilis, ATCC PTA-123017.
This second patent for Kemin s
Euglena gracilis is timely, as both U.S. and global surveys indicate consumers recognize the importance of a strong immune system for overall health and wellness, as well as for maintaining an active, healthy lifestyle.
United-states
India
Singapore
Belgium
Brazil
Iowa
China
Italy
South-africa
San-marino
Russia
Kim-edwards